Comparison of the effect of BTWT1, Btvita and LeishG1 topical products on skin wound healing

Comparison of the effect of BTWT1, Btvita and LeishG1 topical products with zinc oxide ointment (standard drug) on skin wound healing

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240304061158N2

Enrollment

144

Registered

2024-07-23

Start date

2024-01-21

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin wound repair in patients undergoing microneedling and laser rejuvenation.

Interventions

Intervention 1: Intervention group 1: After the surgery in the dermatology and hair specialist's office, which was performed bilaterally, the participants applied the product Btvita manufactured by B

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Performing microneedling or laser rejuvenation procedures and having two similar and bilateral wounds

Exclusion criteria

Exclusion criteria: Suffering from diseases that affect wound healing (such as eczema, psoriasis, anemia or diabetes) Regular use of medications or treatments effective in wound healing (such as anticoagulants, non-steroidal anti-inflammatories, topical steroids). Suffering from immunodeficiency diseases, peripheral vascular disease, history of keloid formation, and those who receive anticoagulant treatment or systemic corticosteroids.

Design outcomes

Primary

Measure	Time frame
Pain in wound site. Timepoint: 3rd, 7th, 14th, 21nd days after starting the study. Method of measurement: Visual Analogue Scale.;Erythma. Timepoint: 3rd, 7th, 14th, 21nd days after starting the study. Method of measurement: Visual Analogue Scale.;Exudation. Timepoint: 3rd, 7th, 14th, 42nd and 84th days after starting the study. Method of measurement: Visual Analogue Scale.;Scaling. Timepoint: 3rd, 7th, 14th, 42nd and 84th days after starting the study. Method of measurement: Visual Analogue Scale.;Epithelialization. Timepoint: 3rd, 7th, 14th, 42nd and 84th days after starting the study. Method of measurement: Visual Analogue Scale.	—

Measure

Time frame

Pain in wound site. Timepoint: 3rd, 7th, 14th, 21nd days after starting the study. Method of measurement: Visual Analogue Scale.;Erythma. Timepoint: 3rd, 7th, 14th, 21nd days after starting the study. Method of measurement: Visual Analogue Scale.;Exudation. Timepoint: 3rd, 7th, 14th, 42nd and 84th days after starting the study. Method of measurement: Visual Analogue Scale.;Scaling. Timepoint: 3rd, 7th, 14th, 42nd and 84th days after starting the study. Method of measurement: Visual Analogue Scale.;Epithelialization. Timepoint: 3rd, 7th, 14th, 42nd and 84th days after starting the study. Method of measurement: Visual Analogue Scale.

—

Secondary

Measure	Time frame
Safety. Timepoint: 3rd, 7th, 14th, 21nd days after starting the study. Method of measurement: Doctor examination and patient report.;Beauty appearance. Timepoint: 30 and 60 days after starting the study. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Rashidi

Immunoregulation Research Center

a.rashidi@shahed.ac.ir+98 21 6641 9712

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026